ACP1 Inhibitors
ACP1 inhibitors belong to a distinct chemical class known for their ability to modulate the activity of the human acid phosphatase 1 (ACP1) enzyme. Acid phosphatases are a group of enzymes that catalyze the hydrolysis of phosphoric acid esters under acidic conditions. Their physiological functions encompass a wide range of cellular processes, including signal transduction, cell proliferation, and differentiation. The inhibitors designed to target ACP1 typically possess structural features that allow them to interact with specific binding sites on the enzyme, thereby disrupting its catalytic activity.
The development of ACP1 inhibitors often involves extensive molecular modeling and structure-activity relationship studies to optimize their binding affinity and selectivity.The chemical structures of ACP1 inhibitors can vary widely, reflecting the diverse strategies employed in their design. Researchers focus on understanding the intricate details of the ACP1 enzyme's active site to rationally design inhibitors that can interfere with its function. These inhibitors may exploit various mechanisms, such as competitive or non-competitive inhibition, to modulate ACP1 activity. Additionally, advancements in computational chemistry and high-throughput screening techniques have facilitated the identification and optimization of novel ACP1 inhibitors.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that can indirectly influence ACP1 by inhibiting vascular endothelial growth factor receptors (VEGFRs), which are involved in signal transduction pathways that ACP1 also operates in. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib can block the RAF/MAPK/ERK pathway, indirectly affecting ACP1 which is involved in the same pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a tyrosine kinase inhibitor that can indirectly affect ACP1 by inhibiting Src family kinases, which are part of the same signal transduction pathways. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $110.00 $250.00 $936.00 $50.00 | 33 | |
Quercetin, a plant flavonol, can inhibit phosphatase activity, which includes ACP1, thus modulating cell signaling. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
(-)-Epigallocatechin Gallate can inhibit tyrosine phosphatases such as ACP1, potentially affecting cell signaling. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein can inhibit tyrosine kinases and indirectly affect ACP1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that can indirectly affect ACP1 by inhibiting the RAF/MAPK/ERK pathway, a pathway that ACP1 is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can indirectly affect ACP1 by inhibiting the PI3K/AKT pathway, a pathway that ACP1 is involved in. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can indirectly affect ACP1 by inhibiting the JNK pathway, a pathway that ACP1 is involved in. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine, a potent inhibitor of protein kinases, can indirectly influence ACP1 by inhibiting a broad range of kinases involved in signal transduction pathways that ACP1 is also part of. | ||||||